Biomarkar data analysis to find out patients of lung and head and neck cancer who responded to treatment and who did not respond to treatment
Not Applicable
- Conditions
- Health Condition 1: C148- Malignant neoplasm of overlappingsites of lip, oral cavity and pharynxHealth Condition 2: C349- Malignant neoplasm of unspecifiedpart of bronchus or lung
- Registration Number
- CTRI/2024/03/063428
- Lead Sponsor
- Tata Memorial Centre
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Lung (NSCLC) and oral (OSCC) cancer patients (Histo-pathologically diagnosed) who are slated to undergo anti-PD L1/ neoadjuvant or palliative chemotherapy.
2.Patients can provide sufficient tissues/blood for molecular analysis.
3.Consent from patients for utilization of their tissues and blood for this study.
Exclusion Criteria
1.Pregnant women and patients under the age of 18
2.Those who are unfit to provide biopsy samples as per protocol
3.Those who refuse to consent to tissues being provided for research as per this protocol
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.To develop a method to predict response to anti-PDL 1/ neoadjuvant/ palliative chemo therapy in lung and oral cancer patients. <br/ ><br> <br/ ><br>2.to confirm/ validate/ improve the method to predict response to anti-PDL 1/ palliative/ neoadjuvant chemo therapy in lung and oral cancer patientsTimepoint: At the end of study
- Secondary Outcome Measures
Name Time Method aTimepoint: NA